ASSEMBLY BIOSCIENCES INC
NASDAQ: ASMB (Assembly Biosciences, Inc.)
Last update: 1 hour ago36.60
0.47 (1.30%)
| Previous Close | 36.13 |
| Volume | 156,451 |
| Price / Earnings (Forward) | 16.69 |
| Price / Sales | 7.90 |
| Price / Book | 2.41 |
| 52 Weeks Range |
| Profit Margin | -124.15% |
| Operating Margin (TTM) | -105.54% |
| Diluted EPS (TTM) | -6.20 |
| Quarterly Revenue Growth (YOY) | 62.80% |
| Total Debt/Equity (MRQ) | 11.13% |
| Current Ratio (MRQ) | 2.05 |
| Operating Cash Flow (TTM) | -56.19 M |
| Levered Free Cash Flow (TTM) | -16.50 M |
| Return on Assets (TTM) | -25.49% |
| Return on Equity (TTM) | -133.65% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Assembly Biosciences, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -3.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.17 |
|
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 39.25% |
| % Held by Institutions | 12.77% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Seven Fleet Capital Management Lp | 30 Jun 2026 | 433,147 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |